Fredun Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE194R01017
  • NSEID:
  • BSEID: 539730
INR
2,249.55
-73.65 (-3.17%)
BSENSE

Jun 11, 03:30 PM

BSE+NSE Vol: 9.54 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Cr
Consolidate Annual Results
Mar'25
Net Sales
456.27
Other Operating Income
0.00
Total Operating income
456.27
Raw Material Cost
323.98
Purchase of Finished goods
0.00
(Increase) / Decrease In Stocks
6.05
Employee Cost
22.23
Power Cost
0.00
Manufacturing Expenses
17.56
Selling and Distribution Expenses
0.00
Other Expenses
31.54
Total Expenditure (Excl Depreciation)
401.36
Operating Profit (PBDIT) excl Other Income
54.91
Other Income
0.00
Operating Profit (PBDIT)
54.91
Interest
22.38
Exceptional Items
0.00
Gross Profit (PBDT)
32.53
Depreciation
5.04
Profit Before Tax
27.49
Tax
7.75
Provisions and contingencies
0.00
Profit After Tax
19.74
Extraordinary Items
0.00
Prior Period Expenses
0.00
Other Adjustments
0.00
Net Profit
19.74
Share in Profit of Associates
0.00
Minority Interest
0.00
Other related items
0.00
Consolidated Net Profit
19.74
Equity Capital
4.72
Face Value
10.0
Reserves
136.68
Earnings per share (EPS)
41.82
Diluted Earnings per share
44.83
Operating Profit Margin (Excl OI)
12.16%
Gross Profit Margin
7.2%
PAT Margin
4.37%
Public Share Holdings (%)
51.07%
Pledged Promotor Holding (%)
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is 40.21% vs 30.33% in Mar 2025

stock-summary

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 59.59% vs 33.23% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is 72.05% vs 41.65% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is 75.60% vs 63.96% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Mar 2026 has improved from Mar 2025

Compare Annual Results Of Fredun Pharma With
Markets Mojo
Figures in Cr
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
456.27
489.17
-32.90
-6.73%
Other Operating Income
0.00
0.00
0.00
Total Operating income
456.27
489.17
-32.90
-6.73%
Raw Material Cost
323.98
220.94
103.04
46.64%
Purchase of Finished goods
0.00
67.23
-67.23
-100.00%
(Increase) / Decrease In Stocks
6.05
-3.89
9.94
255.53%
Employee Cost
22.23
67.09
-44.86
-66.87%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
17.56
-0.01
17.57
175,700.00%
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
31.54
60.38
-28.84
-47.76%
Total Expenditure (Excl Depreciation)
401.36
411.74
-10.38
-2.52%
Operating Profit (PBDIT) excl Other Income
54.91
77.43
-22.52
-29.08%
Other Income
0.00
31.34
-31.34
-100.00%
Operating Profit (PBDIT)
54.91
108.77
-53.86
-49.52%
Interest
22.38
1.16
21.22
1,829.31%
Exceptional Items
0.00
0.04
-0.04
-100.00%
Gross Profit (PBDT)
32.53
107.65
-75.12
-69.78%
Depreciation
5.04
6.53
-1.49
-22.82%
Profit Before Tax
27.49
101.12
-73.63
-72.81%
Tax
7.75
24.68
-16.93
-68.60%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
19.74
76.44
-56.70
-74.18%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
19.74
76.44
-56.70
-74.18%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
19.74
76.44
-56.70
-74.18%
Equity Capital
4.72
94.00
-89.28
-94.98%
Face Value
10.00
1.00
0.00
Reserves
136.68
320.99
-184.31
-57.42%
Earnings per share (EPS)
41.82
0.81
41.01
5,062.96%
Diluted Earnings per share
44.83
0.81
44.02
5,434.57%
Operating Profit Margin (Excl OI)
12.16%
15.83%
0.00
-3.67%
Gross Profit Margin
7.20%
22.01%
0.00
-14.81%
PAT Margin
4.37%
15.63%
0.00
-11.26%
Public Share Holdings (%)
51.07%
0.00%
51.07
51.07%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 633.33 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 40.21% vs 30.33% in Mar 2025

Annual - Standalone Net Profit
Standalone Net Profit 33.21 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 59.59% vs 33.23% in Mar 2025

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 94.80 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 72.05% vs 41.65% in Mar 2025

Annual - Interest
Interest 39.30 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 75.60% vs 63.96% in Mar 2025

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 14.97%
in Mar 2026

Figures in %
stock-summary

YoY Growth in year ended Mar 2026 has improved from Mar 2025